AlphAIalphai — Financial news for AI agents
MarketBeatMAR 292 min read$LIVN

Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN

Tudor Investment Corp ET AL recently acquired a new stake of 33,332 shares in LivaNova PLC (LIVN) during the third quarter, valued at approximately $1.75 million. Institutional ownership of LivaNova is high at 97.64%, with other firms like Parkman Healthcare Partners LLC also significantly increasing their holdings. LivaNova reported strong Q3 earnings, beating analyst estimates, and provided positive FY2026 guidance, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $74.78.

Original reporting
MarketBeat · MarketBeat
Published Mar 29, 2026, 11:31 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 29, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN — source image
Source · MarketBeat
Decision brief

The 30-second read

$LIVNBullishHigh
01

Why it matters

Institutional buying signals confidence in future earnings, potentially leading to stock appreciation.

02

Market read

The news indicates a positive shift in institutional sentiment, likely to influence short- to medium-term trading activity.

03

What to watch

Potential regulatory risks or macroeconomic factors that could offset gains.

Timing: Immediate to short-term (next 1-3 months)

Background

LivaNova PLC has shown consistent earnings growth, supported by innovation in medical devices.

Company-level read

Ticker impact

$LIVNBullishHigh confidence
Context

High relevance due to recent institutional buying, strong earnings report, and positive guidance.

Expected impact

Moderate upward price movement over the next 1-3 months.

Evidence & confidence

Institutional buying often precedes price appreciation, especially when combined with strong earnings and positive guidance.

Market effects

Sector

Positive for the medical device and life sciences sector, indicating investor confidence.

Regional

Limited regional impact; primarily affects investors in the company's primary markets.

Global

Moderate; reflects global investor interest in healthcare stocks.

Counterpoint

What could challenge this read

The positive news may already be priced in; potential for short-term correction if broader market declines.

Key entities

  • Company
    LivaNova PLC

    A global medical technology company specializing in medical devices.

  • Institutional Investor
    Tudor Investment Corp

    A hedge fund that increased its stake in LIVN.

Read at source← All news

Related articles

AUG 7
$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

yahoo.com7 min
AUG 5
$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

yahoo.com6 min
AUG 5
$LIVNHighAI 9/10

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.

finanznachrichten.de7 min
AUG 5
$LIVNHighAI 9/10

Why is LivaNova stock climbing today?

LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.

investing.com3 min
AUG 5
$LIVNHigh

LivaNova PLC (LIVN): Results of Operations and Financial Condition

LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev

SEC EDGAR 8-K6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min